Patents Issued in August 14, 2003
  • Publication number: 20030153541
    Abstract: Compositions, methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The compositions, methods, combinations, and kits of the present invention are pharmaceutical compositions comprising at least two of an LXR receptor modulator, a therapeutically effective amount of a catechin, and/or a therapeutically effective amount of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibric acid derivative, niacin, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivatives, an azetidinone compound, and an unsaturated omega-3 fatty acid.
    Type: Application
    Filed: June 19, 2002
    Publication date: August 14, 2003
    Inventors: Robert Dudley, Shutsung Liao, Ching Song
  • Publication number: 20030153542
    Abstract: There is provided a crystalline chemical composition comprising a compound of formula (I) 1
    Type: Application
    Filed: February 4, 2002
    Publication date: August 14, 2003
    Inventors: Keith Biggadike, Steven John Coote, Andrew S. Craig, Victor W. Jacewicz, Michael J. Millan, Rosalyn K. Nice, Brian M. Noga, John F. Seager, Andrew L. Theophilus, David M. Crowe
  • Publication number: 20030153543
    Abstract: Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.
    Type: Application
    Filed: December 19, 2002
    Publication date: August 14, 2003
    Inventors: Masato Tanabe, Richard H. Peters, Wan-Ru Chao, Ling Jong
  • Publication number: 20030153544
    Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH 2 O—, RCH 2 NH—, —COOCH 2 R, —CONHCH 2 R and —SCH 2 R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.
    Type: Application
    Filed: April 5, 2002
    Publication date: August 14, 2003
    Inventors: Finn Myhren, Bernt Borretzen, Are Dalen, Marit Liland Sandvold
  • Publication number: 20030153545
    Abstract: The present invention provides methods of making 21-[4′-(nitrooxyalkyl)benzoate] corticosteroid derivatives according to the following general reaction scheme: 1
    Type: Application
    Filed: May 21, 2002
    Publication date: August 14, 2003
    Inventor: Donald G. McIntyre
  • Publication number: 20030153546
    Abstract: The invention relates to compounds of the formula: 1 (I) 1 R1 = R2 = R3 = R4 = —CH3 T4MPyP —CH3 —CH2(CH2)4CH3 mono-C6 —CH2(CH2)8CH3 mono-C10 —CH2(CH2)12CH3 mono-C14 —CH2(CH2)16CH3 mono-C18 —CH2(CH2)20CH3 mono-C22 2 mono-benzyl R1 = R2 = R3 = R4 = tetra-CS —CH2(CH2)4CH3
    Type: Application
    Filed: January 29, 2003
    Publication date: August 14, 2003
    Inventors: Moshe Schaffer, Giulio Jori, Alexander Holtz
  • Publication number: 20030153547
    Abstract: The invention relates to a polymeric micellar structure comprising an ionic porphyrin dendrimer represented by general formula [1]
    Type: Application
    Filed: October 18, 2002
    Publication date: August 14, 2003
    Inventors: Takuzo Aida, Dong-Lin Jiang, Daisuke Ohno, Hendrick Stapert, Nobuhiro Nishiyama, Kazunori Kataoka
  • Publication number: 20030153548
    Abstract: The invention relates to a method of treating a diabetic condition by administering a therapeutically effective amount of a histamine-3 receptor antagonist, including benzofuran and benzopyran derivatives of formula (I), aminoalkoxybiphenylcarboxamide compounds of formula (III), and aminoetherbiphenyl compounds of formula (IV) as described herein.
    Type: Application
    Filed: December 23, 2002
    Publication date: August 14, 2003
    Inventors: Arthur A. Hancock, Eugene N. Bush, Marlon D. Cowart, Peer B. Jacobson, Terry J. Opgenorth, Youssef Bennani
  • Publication number: 20030153549
    Abstract: The invention relates to compounds of formula (I) wherein each of X, Y and Z, which may be the same or different, represents hydrogen or an unsubstituted or substituted hydrocarbon radical, typically an alkyl, aryl, including heterocyclic aryl, or non-aromatic heterocyclic radical and Y additionally may represent —COWR wherein W represents O, S or NRiv wherein Riv represents hydrogen or a radical R, and R represents hydrogen or an unsubstituted or substituted hydrocarbon radical for use as protease inhibitors, X, Y and Z being chosen so that they do not react covalently prior to reaction of the &bgr;-lactam ring with the target protease.
    Type: Application
    Filed: January 21, 2003
    Publication date: August 14, 2003
    Inventors: Christopher Joseph Schofield, Rupert Charles Wilmouth
  • Publication number: 20030153550
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Application
    Filed: October 7, 2002
    Publication date: August 14, 2003
    Inventors: James E. Audia, Richard C. Thompson, Stephen C. Wilkie, Thomas C. Britton, Warren J. Porter, George W. Huffman, Lee H. Latimer
  • Publication number: 20030153551
    Abstract: The invention provides a method for causing regression of ocular neovascularization in a subject by administering an effective amount of a staurosporine derivative to the subject.
    Type: Application
    Filed: February 11, 2003
    Publication date: August 14, 2003
    Inventor: Romulus Kimbro Brazzell
  • Publication number: 20030153552
    Abstract: An essentially pure noribogaine compound having the formula: 1
    Type: Application
    Filed: February 14, 2002
    Publication date: August 14, 2003
    Inventors: Deborah C. Mash, Juan Sanchez-Ramos, William Lee Hearn
  • Publication number: 20030153553
    Abstract: Compounds of general formula I 1
    Type: Application
    Filed: February 4, 2003
    Publication date: August 14, 2003
    Inventors: Patrizio Mattei, Werner Mueller, Werner Neidhart, Matthias Heinrich Nettekoven, Philippe Pflieger
  • Publication number: 20030153554
    Abstract: The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.
    Type: Application
    Filed: January 24, 2003
    Publication date: August 14, 2003
    Inventors: Thomas E. Jenkins, Sabine Axt, Jennifer Bolton
  • Publication number: 20030153555
    Abstract: The invention provides compounds of general formula (I) wherein m, n, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 17, 2002
    Publication date: August 14, 2003
    Inventors: Tomas Eriksson, Krister Henriksson
  • Publication number: 20030153556
    Abstract: Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.
    Type: Application
    Filed: September 6, 2002
    Publication date: August 14, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Daniel E. Levy, Mark S. Smyth, Robert M. Scarborough
  • Publication number: 20030153557
    Abstract: The present invention relates to thienyl substituted acylguanidine derivatives, such as compounds of formula (I) in which R1, R2, R4, R6, A, B and D have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the present invention are valuable pharmaceutical active compounds. They are vitronectin receptor antagonists and inhibitors of bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of thienyl substituted acylguanidines, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: November 14, 2002
    Publication date: August 14, 2003
    Applicant: Aventis Pharma Deutschland GmbH and Genentech, Inc.
    Inventors: Karl-Heinz Scheunemann, Jochen Knolle, Amuschirwan Peyman, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Publication number: 20030153558
    Abstract: The present invention relates to 4-pyridyl- und 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy, of the formula 1 1
    Type: Application
    Filed: November 5, 2002
    Publication date: August 14, 2003
    Inventors: Hans-Guenter Striegel, Stefan Laufer, Karola Tollmann, Susanne Tries
  • Publication number: 20030153559
    Abstract: The invention refers to novel propenecarboxylic acid amidoxime derivatives furthermore N-oxides and/or geometrical isomers and/or optical isomers and/or pharmaceutically suitable acid addition salts and/or quaternary derivatives thereof. The novel compounds are suitable for the treatment of a state connected with oxygen deficit and/or energy deficit, or a disease based on PARP inhibition, especially an autoimmune or neurodegenerative disease, and/or a viral disease, and/or a disease caused by a toxic effect.
    Type: Application
    Filed: November 20, 2002
    Publication date: August 14, 2003
    Inventors: Peter Literati Nagy, Balazs Sumegi, Kalman Takacs
  • Publication number: 20030153560
    Abstract: The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: October 23, 2001
    Publication date: August 14, 2003
    Inventors: Francesco G. Salituro, Guy W. Bemis, Susanne Wilke, Jeremy Green, Jingrong Cao, Huai Gao, Edmund Martin Harrington
  • Publication number: 20030153561
    Abstract: The present invention provides a compound of formula I 1
    Type: Application
    Filed: November 5, 2002
    Publication date: August 14, 2003
    Inventors: Valerie A. Vaillancourt, Sandra Staley, Audris Huang, Richard Allen Nugent, Ke Chen, Sajiv K. Nair, James A. Nieman, Joseph Walter Strohbach
  • Publication number: 20030153562
    Abstract: A class of substituted imadazolo[2,1-a]phthalazine derivatives as ligands for GABAA receptors which are partial or full inverse agonists of an &agr;5 receptor subunit while being relatively free of activity at &agr;1 and/or &agr;2 and/or &agr;3 receptor subunit binding sites; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of proconvulsant activity.
    Type: Application
    Filed: January 16, 2003
    Publication date: August 14, 2003
    Inventors: William Robert Carling, Tamara Ladduwahetty, Angus Murray MacLeod, Austin John Reeve, Francine Sternfeld
  • Publication number: 20030153563
    Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animal, such as stroke.
    Type: Application
    Filed: November 14, 2002
    Publication date: August 14, 2003
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Mustapha Haddach, John Patrick Williams, Michael K. Schwaebe
  • Publication number: 20030153564
    Abstract: There is provided compounds of formula I, 1
    Type: Application
    Filed: December 12, 2002
    Publication date: August 14, 2003
    Applicant: AstraZeneca AB
    Inventors: Annika Bjore, Magnus Bjorsne, David Cladingboel, Kurt-Jurgen Hoffmann, John Pavey, Fritiof Ponten, Gert Strandlund, Peder Svensson, Colin Thomson, Michael Wilsterman
  • Publication number: 20030153565
    Abstract: Compounds of the formula (1), in which the substituents have the meanings mentioned in the description, are valuable intermediates for preparing active compounds for the prevention and treatment of gastrointestinal diseases.
    Type: Application
    Filed: September 19, 2002
    Publication date: August 14, 2003
    Inventors: Jorg Senn-Bilfinger, Wilm Buhr, Peter Zimmermann
  • Publication number: 20030153566
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: December 2, 2002
    Publication date: August 14, 2003
    Inventors: Alexander Flohr, Roland Jakob-Roetne, Roger David Norcross, Claus Riemer
  • Publication number: 20030153567
    Abstract: Novel N-phenyl imidazole derivatives, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists are described.
    Type: Application
    Filed: January 29, 2003
    Publication date: August 14, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: John Duncan Elliott, Joseph Weinstock, Jia-Ning Xiang
  • Publication number: 20030153568
    Abstract: The present invention is directed to a compound of formula (I), 1
    Type: Application
    Filed: February 6, 2001
    Publication date: August 14, 2003
    Applicant: BASF Aktiengesellschaft Ludwigshafen, Germany
    Inventors: Kevin P. Cusack, Barbara Scott, Lee D. Arnold, Anna M. Ericsson
  • Publication number: 20030153569
    Abstract: Novel pyridyl and pyrimidinyl substituted pyrazole and pyrazoline compounds and compositions for use in therapy.
    Type: Application
    Filed: February 19, 2003
    Publication date: August 14, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Timothy Gallagher, Irennegbe Kelly Osifo
  • Publication number: 20030153570
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: October 30, 2002
    Publication date: August 14, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
  • Publication number: 20030153571
    Abstract: A method for the treatment of pain is disclosed comprising administration of a pain-ameliorating effective amount of any compound according to structural diagram I; 1
    Type: Application
    Filed: December 17, 2002
    Publication date: August 14, 2003
    Inventors: Dean Gordon Brown, Thomas Michael Bare, Megan Murphy, Rebecca Ann Urbanek, Wenhua Xiao, Marie Frances McLaren, Carey Lynn Horchler
  • Publication number: 20030153572
    Abstract: Compounds according to structural diagram I are disclosed; 1
    Type: Application
    Filed: February 12, 2003
    Publication date: August 14, 2003
    Inventors: Megan Murphy, Rebecca Ann Urbanek, Wenhua Xiao, Gary Banks Steelman, Dean Gordon Brown, Thomas Michael Bare
  • Publication number: 20030153573
    Abstract: This invention concerns the compounds of formula 1
    Type: Application
    Filed: November 19, 2002
    Publication date: August 14, 2003
    Inventors: Jean-Paul Rene Marie Bosmans, Christopher John Love, Marc Gustaaf Celine Verdonck, Joannes Adrianus Jacobus Schuurkes
  • Publication number: 20030153574
    Abstract: Compound corresponding to the general formula (I) 1
    Type: Application
    Filed: February 24, 2003
    Publication date: August 14, 2003
    Inventors: Frederic Galli, Alistair Lochead, Axelle Samson
  • Publication number: 20030153575
    Abstract: Compounds of a general structural formula (I) and salts and solvates thereof, and use of the compounds as PDES inhibitor.
    Type: Application
    Filed: November 22, 2002
    Publication date: August 14, 2003
    Inventors: Mark W. Orme, Alain Claude-Marie Daugan, Agnes Bombrun
  • Publication number: 20030153576
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I):
    Type: Application
    Filed: December 19, 2001
    Publication date: August 14, 2003
    Inventors: Albert J. Robichaud, Ian S. Mitchell
  • Publication number: 20030153577
    Abstract: This invention relates to certain cyclic amine derivatives of Formula (I) 1
    Type: Application
    Filed: August 29, 2001
    Publication date: August 14, 2003
    Applicant: Roche Bioscience
    Inventors: Leyi Gong, Donald Roy Hirschfeld, Denis John Kertesz, David Bernard Smith, Francisco Xavier Talamas, Robert Stephen Wilhelm
  • Publication number: 20030153578
    Abstract: The invention provides compounds of Formula (I): 1
    Type: Application
    Filed: November 27, 2002
    Publication date: August 14, 2003
    Inventors: Daisy Joe Du Bois, Beihan Wang
  • Publication number: 20030153579
    Abstract: A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) 1
    Type: Application
    Filed: September 23, 2002
    Publication date: August 14, 2003
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Hisao Tajima, Yoshisuke Nakayama, Daikichi Fukushima
  • Publication number: 20030153580
    Abstract: The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.
    Type: Application
    Filed: December 11, 2002
    Publication date: August 14, 2003
    Inventors: Norman Kong, Emily Aijun Liu, Binh Thanh Vu
  • Publication number: 20030153581
    Abstract: An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCI, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection site.
    Type: Application
    Filed: January 17, 2003
    Publication date: August 14, 2003
    Applicant: Wyeth
    Inventor: Henderik W. Frijlink
  • Publication number: 20030153582
    Abstract: A method and composition for treating irritable bowel syndrome in a subject in need of such treatment, utilizing an amount of a polyamine having the formula:
    Type: Application
    Filed: August 1, 2002
    Publication date: August 14, 2003
    Inventor: Raymond J. Bergeron
  • Publication number: 20030153583
    Abstract: Crystalline forms of the p38 kinase inhibitor N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole are provided. These crystalline forms include (a) a first anhydrous crystalline form possessing improved physical stability relative to other solid-state forms of the compound; (b) a second anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; (c) a third anhydrous crystalline form possessing unique properties relative to other solid-state forms of the compound; and (d) solvated crystalline forms, hydrated crystalline forms, and crystalline salt forms of the compound that are useful, for example, as intermediate solid-state forms in the preparation of other crystalline forms of the compound.
    Type: Application
    Filed: September 25, 2002
    Publication date: August 14, 2003
    Inventors: Kimberley C. Allen, Jerry D. Clark, Thomas P. Fraher, Jason A. Hanko, Kimberly L. Kolbert, Clay R. Little, Michael K. Mao, Patricia S. Miyake, Jodi L. Moe, Partha S. Mudipalli, Tobin C. Schilke, Christine B. Seymour, Ahmad Y. Sheikh, Gopichand Yalamanchili
  • Publication number: 20030153584
    Abstract: Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described.
    Type: Application
    Filed: April 11, 2002
    Publication date: August 14, 2003
    Applicant: Queen's University
    Inventors: Donald F. Weaver, Buhendwa Musole Guillain, John R. Carran, Kathryn Jones
  • Publication number: 20030153585
    Abstract: The invention relates to pharmaceutical preparations comprising at least one medicament active ingredient and 2-pyrrolidone as solubilizer.
    Type: Application
    Filed: November 1, 2002
    Publication date: August 14, 2003
    Inventors: Sven-Alexander Schreder, Claudia Wildner, Karen Schamp
  • Publication number: 20030153586
    Abstract: The present invention provides compounds of the formula: 1
    Type: Application
    Filed: August 29, 2002
    Publication date: August 14, 2003
    Applicant: Syntex (U.S.A) LLC
    Inventors: Jian Jeffrey Chen, James Patrick Dunn, David Michael Goldstein, Julie Anne Lim
  • Publication number: 20030153587
    Abstract: A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.
    Type: Application
    Filed: August 26, 2002
    Publication date: August 14, 2003
    Applicant: Schering Corporation
    Inventors: Theodros Asberom, Yueqing Hu, Dmitri Pissarnitski, Ruo Xu, Yuguang Wang, Samuel Chackalamannil, John W. Clader, Andrew William Stamford
  • Publication number: 20030153588
    Abstract: Compounds of formula (I) wherein X is O, CH2, S or NH, or the moiety X—R1 is hydrogen; V is CH or N; R1 is hydrogen, C1-6-alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heterocyclyl, heterocyclylC1-6alkyl, heteroaryl, or heteroarylC1-6alkyl any of which except for hydrogen may be optionally substituted; R2 and R3 independently represent optionally substituted C1-6-alkyl, or R2 and R3 together with the carbon atom to which they are attached form an optionally substituted C3-7cycloalkyl or C3-7cycloalkenyl ring; or R2 and R3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.
    Type: Application
    Filed: January 7, 2003
    Publication date: August 14, 2003
    Inventors: Jon Graham Steadman, Andrew Kenneth Takle
  • Publication number: 20030153589
    Abstract: Methods of providing neuroprotection are disclosed comprising administering a non-sedative barbiturate compound in an amount sufficient to achieve neuroprotection in a mammalian subject. Preferred compounds are in the family of diphenylbarbituric acid and analogs.
    Type: Application
    Filed: January 27, 2003
    Publication date: August 14, 2003
    Inventors: Daniel A Moros, Barrie Levitt, Avraham Yacobi
  • Publication number: 20030153590
    Abstract: The present invention relates to a method of treating alcoholism or alcohol abuse by administering to a subject a pharmaceutically effective amount of an opioid antagonist before imminent drinking. Particularly, the present invention relates to a method of treating alcoholism or alcohol abuse by administering transmucosally to a subject a pharmaceutically effective amount of an opioid antagonist before imminent drinking. Preferably, the opioid antagonist used in the method is nalmefene or a pharmaceutically acceptable salt thereof. The invention also relates to a method of treating alcoholism or alcohol abuse by administering to a subject before imminent drinking a transmucosal preparation comprising a pharmaceutically effective amount of an opioid antagonist, wherein the transmucosal preparation has rapid onset of action. Advantageously, a FAH+ subject is treated.
    Type: Application
    Filed: August 13, 2002
    Publication date: August 14, 2003
    Applicant: OY CONTRAL PHARMA LTD
    Inventors: Kauko O.A. Kurkela, Olli Puhakka, Tuuli I. Sonck, Sakari Karhuvaara